Svenska
Home
About
Active Biotech in Brief
Board of Directors
Management
Business Concept
Corporate Governance
Corporate Governance Report 2019
Article of Association
Audit committee
Scientific committee
Election Committee
General Meetings
Auditors
Partnerships
Career
Projects
Project Overview
Naptumomab
Tasquinimod
Laquinimod
Patents
Orphan Drug Designation
Investor
Investor
Analyst coverage
Financial Calendar
Financial Reports
Interim Reports
Annual Reports
Stock
Ownership
Official Documents
Rights Issue 2014
Rights Issue 2016
Rights Issue 2018
Rights Issue 2021
Media
Press Contact
Press Releases
Subscribe
News
Company Presentation
Image Bank
Contact
Copyright © 2021 Active Biotech AB.
All Rights Reserved.
Design by
Clavis Communications
.
Media
Press Contact
Press Releases
News
Company Presentation
Image Bank
News
Active Biotech’s presentation at Solebury Trout European Biotech Investor Days 2021
April 8, 2021
Number of shares and votes in Active Biotech
March 31, 2021
Number of shares and votes in Active Biotech
March 2, 2021
Active Biotech Year-end report January – December 2020
February 11, 2021
Active Biotech enters into a manufacturing agreement with Famar Health Care Services for new formulation of Laquinimod
February 4, 2021
Active Biotech’s rights issue heavily oversubscribed
January 26, 2021
Adjustment of period for trading in subscription rights and interim shares in Active Biotech’s rights issue
January 7, 2021
Active Biotech publishes prospectus and certain new financial information included in the prospectus
January 5, 2021
Redeye initiates coverage of Active Biotech, see analysis
December 14, 2020
Active Biotech Receive Milestone Payment From NeoTX
December 11, 2020
Active Biotech’s presentation at Life Science Day 2020 (in Swedish)
December 2, 2020
Active Biotech’s nomination committee appointed
December 1, 2020
Report from extraordinary general meeting in Active Biotech and adjustment of previously communicated timetable for the rights issue
November 30, 2020
Active Biotech announces the final terms of the rights issue
November 25, 2020
Active Biotech updates its clinical strategy and projected milestones
November 24, 2020
Invitation to Active Biotech’s virtual capital markets day
November 6, 2020
Notice of extraordinary general meeting in Active Biotech
November 5, 2020
Active Biotech carries out rights issue
November 5, 2020
Active Biotech Interim report January – September 2020
November 5, 2020
Active Biotech Interim Report January – June 2020
August 6, 2020
Active Biotech announces first patient dosed in phase 1b/2a study of tasquinimod use in treatment of multiple myeloma
August 3, 2020
Tasquinimod demonstrates potent anti-tumor activity in experimental models for multiple myeloma. Data will be presented at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress Meeting, taking place June 11-21 2020
June 12, 2020
Presentation – new direction
June 3, 2020
New pre-clinical data on laquinimod in an experimental autoimmune uveitis model has been published as an abstract in the Journal of Immunology. May 1, 2020, 204 (1 Supplement) 150.18.
June 3, 2020
Active Biotech provides status update in the portfolio projects
June 3, 2020
Annual General Meeting of Active Biotech AB
May 19, 2020
Annual Report 2019
April 24, 2020
Notice of annual general meeting of shareholders on Tuesday, May 19, 2020
April 20, 2020
Active Biotech AB – Year-end report January – December 2019
February 6, 2020
Active Biotech announces new direction
February 5, 2020
Active Biotech’s election committee appointed
November 19, 2019
Active Biotech Interim report January – September 2019
November 14, 2019
New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting
November 5, 2019
Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors
October 28, 2019
New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders
September 23, 2019
Active Biotech AB: Interim report January – June 2019
August 8, 2019
The Annual General Meeting of Active Biotech was held on May 23, 2019
May 24, 2019
The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “American Academy of Neurology – AAN” in Philadelphia, PA, on May 6 2019
May 3, 2019
The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board
May 2, 2019
Annual Report 2018 Active Biotech AB (publ)
April 26, 2019
Active Biotech AB – Interim report January – March 2019
April 25, 2019
Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
April 24, 2019
Active Biotech completes sale of property
April 5, 2019
An Extraordinary General Meeting of Active Biotech AB was held on April 4, 2019
April 5, 2019
Active Biotech has entered into an agreement regarding sale of the Company’s property – extraordinary general meeting on April 4, 2019
March 13, 2019
Active Biotech Year-end report January – December 2018
February 14, 2019
Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
February 11, 2019
Active Biotech has received an indicative bid for the property in Lund – the Board is positive
February 1, 2019
Active Biotech provides updated information about the company’s financial position
December 10, 2018
Interim report January – September 2018
November 15, 2018
This site uses cookies.
Okay, thanks